Carisma Therapeutics (CARM) Price & Analysis

Q: What was Carisma Therapeutics’s price range in the past 12 months?

Carisma Therapeutics lowest stock price was $0.03 and its highest was $1.27 in the past 12 months.

Q: What is Carisma Therapeutics’s market cap?

Carisma Therapeutics’s market cap is $1.76M.

Q: When is Carisma Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Carisma Therapeutics overvalued?

According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Carisma Therapeutics pay dividends?

Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here

Q: What is Carisma Therapeutics’s EPS estimate?

Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Carisma Therapeutics have?

Carisma Therapeutics has 41,845,078 shares outstanding.

Q: Which hedge fund is a major shareholder of Carisma Therapeutics?

Currently, no hedge funds are holding shares in CARM

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

1,724 Followers

CARM Stock Chart & Stats

$0.04

-$0.04(-7.53%)

At close: Jan 08 4:00 PM EST

$0.04

-$0.04(-7.53%)

Day’s Range― - ―

52-Week Range$0.03 - $1.27

Previous CloseN/A

Volume72.54K

Average Volume (3M)2.25M

Market Cap

$1.76M

Enterprise Value$0.00

Total Cash (Recent Filing)$2.78M

Total Debt (Recent Filing)$762.00K

Price to Earnings (P/E)0.2

Beta1.93

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding41,845,078

10 Day Avg. Volume3,913,183

30 Day Avg. Volume2,245,153

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.62

Price to Sales (P/S)0.88

P/FCF Ratio-0.29

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.

Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.

Bears Say

Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.

Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.

Carisma Therapeutics News

Carisma Therapeutics Announces Nasdaq Delisting and Leadership Changes

The latest announcement is out from Carisma Therapeutics ( ($CARM) ). Carisma Therapeutics Inc. announced the voluntary delisting...

1M ago

CARM

Carisma Therapeutics announces Nasdaq delisting, SEC deregistration

Carisma Therapeutics (CARM)’ Board of Directors has approved and the Company intends to proceed with the voluntary delisting...

1M ago

CARM

Carisma Therapeutics Announces Executive Terminations and Wind-Down

An announcement from Carisma Therapeutics ( ($CARM) ) is now available. Carisma Therapeutics Inc. announced plans to wind...

3M ago

CARM

Insider Moves: Ross, Carisma, Agree, Aehr, Ocular

Insiders have been trading these 5 stocks: (($ROST)), (($CARM)), (($ADC)), (($AEHR)) and (($OCUL)). Here is a breakdown of...

3M ago

ADC

AEHR

Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension

Carisma Therapeutics ( ($CARM) ) has provided an update. On October 9, 2025, Carisma Therapeutics Inc. received a...

3M ago

CARM

Carisma Therapeutics Amends Agreement with Moderna

An update from Carisma Therapeutics ( ($CARM) ) is now available. On September 16, 2025, Carisma Therapeutics Inc....

4M ago

CARM

Why Is Carisma Therapeutics Stock (CARM) Up 165% Today?

Carisma Therapeutics stock rallied on Tuesday after the company announced an update to its merger with OrthoCellix. ...

5M ago

CARM

OCGN

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors are back in the saddle after an extended weekend, and there’s plenty of stock market news to catch up on. ...

5M ago

AMD

BLK

Carisma Therapeutics Announces Merger with OrthoCellix

The latest announcement is out from Carisma Therapeutics ( ($CARM) ). On August 29, 2025, Carisma Therapeutics Inc....

5M ago

CARM

Carisma Therapeutics Approves Reverse Stock Split

The latest update is out from Carisma Therapeutics ( ($CARM) ). On August 5, 2025, Carisma Therapeutics Inc....

5M ago

CARM

Carisma Therapeutics Transfers Listing to Nasdaq Capital Market

Carisma Therapeutics ( ($CARM) ) just unveiled an announcement. On January 6, 2025, Carisma Therapeutics was notified by...

6M ago

CARM

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a...

7M ago

CARM

OCGN

Carisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps...

10M ago

CARM

Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor downgraded Carisma Therapeutics (CARM) to Neutral from Buy without a price target after...

1y ago

CARM

CARM FAQ

What was Carisma Therapeutics’s price range in the past 12 months?

Carisma Therapeutics lowest stock price was $0.03 and its highest was $1.27 in the past 12 months.

What is Carisma Therapeutics’s market cap?

Carisma Therapeutics’s market cap is $1.76M.

When is Carisma Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Carisma Therapeutics’s earnings last quarter?

Currently, no data Available

Is Carisma Therapeutics overvalued?

According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Carisma Therapeutics pay dividends?

Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here

What is Carisma Therapeutics’s EPS estimate?

Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Carisma Therapeutics have?

Carisma Therapeutics has 41,845,078 shares outstanding.

What happened to Carisma Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Carisma Therapeutics?

Currently, no hedge funds are holding shares in CARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Carisma Therapeutics

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.